

PRESS RELEASE – FOR IMMEDIATE RELEASE

**IntegraGen Obtains Exclusive Worldwide License for Two Molecular Signatures
for Patients with Liver Cancer**

Evry, France (December 2, 2014) - IntegraGen, a leading player in the development and commercialization of molecular diagnostic tests for oncology and autism, today announced that it has entered into an agreement with Inserm Transfert and Paris Descartes University providing the company the worldwide licensing rights for two hepatocellular carcinoma (HCC) molecular signatures which have potential clinical utility for monitoring patients with liver cancer. The signatures are comprised of a set of 55 genes that allow the distinction between benign and malignant liver tumors and their different histological subtypes. One signature is a subset of 16 genes which can be used to classify patients with hepatocellular carcinoma (HCC) into six distinct molecular groups with the ability to study the therapeutic response to treatment within these different groups. The second signature consists of 5 genes and is predictive of the clinical prognosis of patients diagnosed with HCC and treated by surgical resection.

The expression signatures covered by this agreement are a result of research conducted by Jessica Zucman-Rossi, M.D., Ph.D., Professor of Medical Oncology at the Paris Descartes University, Georges Pompidou European Hospital and Director of INSERM Unit 1162 which focuses on the functional genomics of solid tumors. This research was funded in part by the Tumor Identity Cards Program of the National League Against Cancer, Paris Descartes University, and INSERM, with the latter two being co-owners, along with IntegraGen, of the patents covering these signatures. These two academic laboratories have granted IntegraGen the exclusive worldwide license for the use of these patents.

“This agreement is a direct result of the excellent collaboration between the IntegraGen team and researcher from INSERM 1162 led by Professor Zucman-Rossi,” said Dr. Bernard Courtieu, CEO of IntegraGen. “IntegraGen is working with pharmaceutical companies to explore the use of the classification signature in early phase clinical trials for new drugs targeting hepatocellular carcinoma in order to identify patients who may respond to these treatments. Moreover, the 5-gene signature may aid physicians in the implementation of therapeutic strategies for patients with liver cancer.”

A [paper](#) published in the journal *Gastroenterology* in 2013 reported the results of an international multicenter study associated with the 5-gene prognostic signature covered by the current agreement. The authors of this study reported that this signature had better predictive accuracy than other gene expression signatures identified to date for patients with liver cancer. Liver cancer is the sixth most common form of cancer and the third leading cause of cancer death worldwide with approximately 800,000 cases diagnosed annually.

ABOUT INTEGRAGEN

IntegraGen is a company specialized in deciphering the human genome by performing genomic analyses for academic and private laboratories and developing diagnostic tools within the fields of oncology and autism. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISK® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of June 30 2014, IntegraGen had 34 employees and had generated revenue of €5.4 million in 2013. Based in the Evry Genopole, Integragen also has an office in the Cambridge, Massachusetts in the United States.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President, Managing Director

Laurence RIOT LAMOTTE
Directeur Administratif et Financier
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NEWCAP.

Investor and Media relations

Louis-Victor DELOUVRIER
Nicolas MERIGEAU
integragen@newcap.fr
Tel.: +33 (0)1 44 71 94 94